₹169.73
1.13 (0.67%) ▲
as on
as on September 1, 2025 at 9:28 am IST
Day's Low
Day's High
0.42%
Downside
0.48%
Upside
52 Week's Low
52 Week's High
0.43%
Downside
111.34%
Upside
as on September 1, 2025 at 9:28 am IST
Market Cap
₹7,640.34 Cr
Return on Equity (ROE)
14.45
PE Ratio (TTM)
21.81
Return on capital employed (ROCE)
18.55
Industry PE ratio
42.75
Beta (LTM)
1.35
P/B Ratio
7.28
Dividend Yield
0.36
PEG Ratio
60.59
Quarterly Earnings Growth YOY
-34.66
EPS (TTM)
8.44
Sector
Pharmaceuticals
Book Value
54.44
Technical Analysis
Bearish
View Technical Analysis
as on September 1, 2025 at 9:28 am IST
Marksans Pharma in the last 5 years
Lowest (4.67x)
April 1, 2020
Today (21.81x)
August 29, 2025
Industry (42.75x)
August 29, 2025
Highest (46.60x)
January 24, 2018
Today’s Price to Earnings Ratio: 21.81x
Compare market cap, revenue, PE, and other key metrics of Marksans Pharma with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
---|---|---|---|---|---|---|
BUY | 7,640.34 | 52.67% | 0.56 | 382 | 2,622 | |
BUY | 24,383.73 | -0.69% | 0.69 | 91 | 9,151 | |
NA | 2,001.19 | 10.88% | 0.00 | NA | NA | |
NA | 10.77 | -9.92% | 0.50 | -2 | 35 | |
NA | 286.81 | 142.07% | 0.00 | -4 | 39 |
Based on 3 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 3 analysts, 100% of analysts recommend a 'BUY' rating for Marksans Pharma. Average target price of ₹231.67
Source: S&P Global Market Intelligence
Get share price movements and forecasts by analysts on Marksans Pharma.
What analysts predicted
37.41%UPSIDE
Target Price
₹231.67
Current Price
₹169.73
Analyzed by
3 Analysts
High
₹265
Target
₹231.67
Low
₹210
Marksans Pharma target price ₹231.67, a slight upside of 37.41% compared to current price of ₹169.73. According to 3 analysts rating.
Source: S&P Global Market Intelligence
Investment in Marksans Pharma Ltd Shares on INDmoney has grown by 122.85% over the past 30 days, indicating increased transactional activity.
Time period: to
Change:122.85% versus previous 30 day period
Search interest for Marksans Pharma Ltd Stock has increased by 51% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:51% versus previous 30 day period
Figures in Rupees Crores
Figures in Rupees Crores
Figures in Rupees Crores
Numbers in percentages
Check out the Mutual Funds with significant holdings in Marksans Pharma.
Funds | Holdings | Prev. 5M |
---|---|---|
Kotak Special Opportunities Fund Direct Growth | 2.91% | |
Bandhan Small Cap Fund Direct Growth | 0.4% | |
Kotak MNC Fund Direct Growth | 2.03% | |
UTI Small Cap Fund Direct Growth | 0.83% | |
UTI Aggressive Hybrid Fund-Growth - Direct | 0.53% |
View detailed summary of the earnings and dividend history of Marksans Pharma.
Marksans Pharma Ltd’s net profit fell -34.29% since last year same period to ₹58.32Cr in the Q1 2025-2026. On a quarterly growth basis, Marksans Pharma Ltd has generated -35.59% fall in its net profits since last 3-months.
Read More about Earnings ResultsIn the quarter ending March 2025, Marksans Pharma Ltd has declared dividend of ₹0.80 per share on 19 May 2025 - translating a dividend yield of 0.83%.
Read More about DividendsCheck stock indices that include Marksans Pharma.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
MF Holding Up
Mutual Funds have increased holdings from 3.37% to 3.55% in Jun 2025 quarter
Best in 3 Years
In the last 3 years, MARKSANS has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
Retail Holding Up
Retail Investor have increased holdings from 29.37% to 30.75% in Jun 2025 quarter
Promoter Holding Unchanged
Promoters holdings remained unchanged at 43.87% of holdings in Jun 2025 quarter
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 20.4% return, outperforming this stock by 50.0%
Price Dip
In the last 1 month, MARKSANS stock has moved down by -28.6%
Profit Down
Netprofit is down for the last 3 quarters, 104.56 Cr → 58.32 Cr (in ₹), with an average decrease of 24.5% per quarter
Revenue Fall
Revenue is down for the last 2 quarters, 723.8 Cr → 625.63 Cr (in ₹), with an average decrease of 13.6% per quarter
FII Holding Down
Foreign Institutions have decreased holdings from 11.32% to 11.26% in Jun 2025 quarter
Organisation | Marksans Pharma Ltd |
Headquarters | Mumbai |
Industry | Pharmaceuticals |
CEO | Mark Saldanha |
E-voting on shares | Click here to vote |
Marksans Pharma share price today stands at ₹169.73 as on . Marksans Pharma share today touched a day high of ₹170.55 and a low of ₹169.01.
Marksans Pharma touched a 52 week high of ₹358.7 and a 52 week low of ₹169. Marksans Pharma share price today i.e. is trending at ₹169.73, which is -52.68% down from its 52 week high and 0.43% up from its 52 week low.
Marksans Pharma market capitalisation is ₹7,640.34 Cr as on .
To buy Marksans Pharma shares, you need to follow these steps:
Marksans Pharma trading volume is 72.80K as on . This means that 72.80K shares of Marksans Pharma were bought and sold on the stock market during today's trading session.